Nuwellis (NUWE) Stock News

Nuwellis (NASDAQ:NUWE) announced the termination of its REVERSE-HF clinical trial, which was evaluating ultrafiltration versus IV loop diuretic therapy for fluid management in hospitalized heart failure patients. The company will redirect its focus toward outpatient heart failure care, pediatric, and critical care markets.

The trial, which began in 2022, had enrolled 167 patients before termination. This strategic decision is expected to save $4.0 million over 2.5 years. The company plans to analyze existing data for potential clinical publications. Importantly, the termination was not due to device performance or safety concerns, and the Nuwellis SmartFlow® remains FDA-cleared for fluid overload treatment.

Nuwellis (Nasdaq: NUWE) has been granted U.S. Patent No. 12,357,734 for its innovative blood filtering technology. The patent, titled "Extracorporeal Blood Filtering Machine and Methods," focuses on improving fluid balance calculation accuracy in continuous renal replacement therapy (CRRT) systems.

The patented technology addresses a critical issue in CRRT systems by accounting for varying fluid densities, moving beyond the standard assumption of 1 g/mL. This advancement enables more precise volumetric flow tracking, potentially reducing clinically relevant fluid balance errors.

The patent strengthens Nuwellis' intellectual property portfolio and reinforces its position in the fluid management therapy sector.

Nuwellis (Nasdaq: NUWE) has appointed John Erb as its permanent Chief Executive Officer, effective June 27, 2025. Erb, who has been serving as interim CEO since February 2025, previously held the CEO position from 2015 to 2020. This appointment follows his successful interim leadership period where he demonstrated ability to bring stability and renewed momentum to the medical technology company.

The Board's decision reflects their confidence in Erb's leadership capabilities and his deep understanding of Nuwellis's mission in advancing fluid management solutions. Under his guidance, the company aims to focus on strategic clarity, operational discipline, and sustainable growth.

Nuwellis (NUWE) has completed a $5.0 million public offering, including the full exercise of the overallotment option. The offering consisted of 2,580,667 common shares and 14,085,998 pre-funded warrants, along with accompanying Series A and Series B Warrants. The common stock and warrants were priced at $0.30 per share, while pre-funded warrants were offered at $0.2999. Series A and B Warrants have a $0.30 exercise price and a 5-year exercise period following stockholder approval. Series A Warrants include a one-time price reset provision tied to potential reverse stock splits, while Series B Warrants feature a zero-cash exercise option. Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for the offering.

Nuwellis (NUWE) has priced a $4.3 million public offering consisting of 406,755 common shares and 14,085,998 pre-funded warrants, along with Series A and B Warrants. The offering is priced at $0.30 per share with accompanying warrants, while pre-funded warrants are priced at $0.2999. The Series A and B Warrants allow holders to purchase up to 43,478,259 and 14,492,753 shares respectively, with a $0.30 exercise price and 5-year term following stockholder approval. Series A Warrants include a one-time price reset provision tied to potential reverse stock splits, while Series B Warrants offer a zero-cash exercise option. Ladenburg Thalmann & Co. Inc. is serving as the sole book-runner, with closing expected around June 10, 2025. The company plans to use proceeds for working capital, general corporate purposes, and potential acquisitions.

Nuwellis (NUWE) reported its Q1 2025 financial results with revenue of $1.9 million, up 3% year-over-year. Key highlights include 38% growth in pediatric revenue and 4% increase in consumables utilization. The company achieved significant cost reductions with operating expenses decreasing 31% to $4.1 million. However, gross margin declined to 56.0% from 64.1% in Q1 2024. The company's Aquadex therapy received higher CMS reimbursement, with facility fees increasing nearly four-fold to $1,639 per day effective January 2025. The quarter ended with $2.6 million in cash and no debt, while net loss improved to $3.0 million ($0.69 per share) compared to $3.8 million ($24.11 per share) in Q1 2024.

Nuwellis (NUWE) has finalized a strategic manufacturing agreement with KDI Precision Manufacturing to outsource the assembly of key Aquadex product components. Under the agreement, KDI will take over assembly responsibilities for the Aquadex SmartFlow® Console, AquaFlexFlow® Blood Circuits, and dELC® Catheters. The partnership aims to enhance operational efficiency and reduce costs while maintaining product quality.

KDI, an ISO 13485 certified and FDA registered company founded in 1982, specializes in medical manufacturing with over 80% of its business in healthcare products. To ensure continuity, current Nuwellis assembly employees will be hired by KDI. Notably, KDI's CEO Vitaliy Epshteyn previously served as Nuwellis' SVP of Operations, Engineering, and QA/RA for 6 years.

Nuwellis (NASDAQ: NUWE) has expanded its Aquadex SmartFlow® therapy to two additional pediatric centers in the Southeastern United States, bringing the total to 47 pediatric centers using their fluid management solution. The Aquadex system is designed for controlled fluid removal in patients weighing 20 kg and above, offering a nurse-managed, bedside-compatible therapy for children facing fluid overload. This expansion represents growing recognition of early, precise fluid management as crucial for better outcomes in pediatric care. The technology provides care teams with a gentle approach to managing fluid overload in critically ill children, where the margin for error is particularly narrow.

Nuwellis (Nasdaq: NUWE) has secured U.S. Patent No. 12,280,007 for an innovative self-emptying fluid bag design that enhances clinical workflow efficiency. The patent, issued on April 22, 2025, features a novel siphon mechanism that enables automatic drainage without disconnecting from the scale, maintaining precise weight-based measurements.

The technology aims to reduce manual intervention requirements while preserving system accuracy in treating fluid overload in critically ill patients. While not planned for immediate implementation, the design could be incorporated into future Aquadex SmartFlow system updates, including the Vivian pediatric-focused CRRT device under development.

The patent received a 224-day extension to its standard term from the USPTO, representing one of several initiatives by Nuwellis to expand its intellectual property portfolio and advance fluid management innovation.